NEW REIMAGINED IDENTITY LIFESCIENCES AUSTRALIA REPOSITIONS FOR SECTOR Commences new initiatives in Company Directors training, Standards push and support for Early Career Stage workforce
With
Dr Tim Boyle PhD ChMPP,
Chief Executive Officer
LifeSciences Australia (formerly called ARCS Australia)
SEGMENT
Filmed in Sydney | June 2026
In June 2026, ARCS Australia formally became LifeSciences Australia — a name chosen to reflect the role the organisation plays across Australia’s life sciences sector.
Over more than 40 years, ARCS has grown well beyond its origins as a training and education body for regulatory and clinical specialists. Today, the organisation supports professionals across the entire life sciences sector — from early research through regulation, development and commercialisation — through an expanding range of programs and initiatives.
Following extensive member and stakeholder consultation throughout 2025 the name change was decided aiming to be a clearer, more inclusive identity reflecting the full breadth of Australia’s life sciences workforce and its role as the sector’s professional peak body.
Australian Health Journal was invited to the 2026 ARCS Conference in Sydney and met with Dr Tim Boyle Chief Executive Officer, LifeSciences Australia.
Source: Adapted from the ARCS Australia website
-
Journey of an ICU Nurse on International Nurses Day 2025
Kate Leigh is a clinical nurse at the Sir Charles Gairdner Hospital Intensive Care Unit in Perth, Western Australia, with seven and a half years of experience in intensive care, having started her career in London as a new graduate nurse. Initially focused on haematology, she found herself drawn to ICU after meeting a confident and knowledgeable nurse during a discharge. Inspired by his expertise and assuredness, Kate decided to pursue a transfer to Critical Care after seeing an internal advertisement that highlighted educational opportunities and professional development programs.
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
CASE STUDY: Evolution in the medical device supply chain
For Cardinal Health, a global manufacturer and distributor of medical products, the process begins when products arrive in Australia and are cleared by customs before being stored at their Sydney warehouse. From here, they fulfil orders for various clients, including hospitals and wholesalers, supported by DHL’s logistics services.
